Seven different forms of the enzyme COMT (catechol O-methyltransferase) were found in isolated rat hepatocytes by two-dimensional gel electrophoresis and immunoblotting: five small variants (S-COMT) and two large variants (L-COMT). The identities of these COMT forms were verified by tryptic fingerprinting using MALDI-TOF (matrix-assisted laser-desorption ionizationtime-of-flight) MS, and by amino acid sequencing using ESI-IT-MS/MS (electrospray ionization with ion-trap tandem MS). Analysis of tissue distributions showed that the S-COMT forms were highly expressed in liver and kidney, whereas L-COMT was expressed more strongly in other tissues. Both of the L-COMT forms were found in all of the tissues examined except the heart, which expressed only the most acidic form, and the kidney, which expressed only the most basic form. Subcellular fractionation revealed the presence of both S-COMT and L-COMT in soluble, as well as sedimentable, fractions, suggesting that they should be classified by size rather than (as previously) by localization. Several of the S-COMT forms were N-acetylated, and the two most acidic forms were found to be phosphorylated at Ser 260 . One of the latter was unique to liver cells; the other was also found in kidney, brain and thymus. Among the non-phosphorylated S-COMT forms, one was ubiquitous, one was found in testis and liver, and a third was found in liver, kidney and thymus. No other phosphorylated sites were found, suggesting that the pI differences distinguishing between the various COMT forms are due to some as yet unidentified structural modification(s).
INTRODUCTION
COMT (catechol O-methyltransferase; EC 2.1.1.6), discovered by the pioneer in neuroscience, Julius Axelrod [1] , is an enzyme involved in catecholamine metabolism. COMT catalyses the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, adrenaline (epinephrine) and noradrenaline (norepinephrine). This Omethylation eliminates the biological activity of the catecholamines and initiates one of the major pathways of their degradation. In addition to its role in the metabolism of endogenous substances, COMT is important in the metabolism of catechol drugs used in the treatment of asthma, hypertension and Parkinson's disease. Inhibitors of COMT include tolcapone [2] , entacapone [3] and nebicapone [4] , which together with aromatic amino acid decarboxylase inhibitors prolong the effect of levodopa on patients with Parkinson's disease [5] .
Primates and rodents have a single gene for COMT [6, 7] , but express two tissue-variable isoforms owing to different initiation sites. Rat brain predominantly expresses a membrane-bound fulllength protein of 29.5 kDa, whereas rat liver expresses mainly a soluble variant of 24.5 kDa lacking the N-terminal 43 amino acids that harbour the membrane-anchoring domain. The fulllength form is reportedly associated with microsomes (rough endoplasmic reticulum) and the plasma membrane [7, 8] . The two COMT forms differ in their substrate affinity and preference, the smaller form generally having higher activity and binding more tightly to xenobiotic catechol compounds, whereas the larger form prefers substrates such as dopamine and noradrenaline, suggesting tissue-specific roles for each variant [9] .
In addition to the two variants differing in their expression patterns, there have been several reports on polymorphisms in humans. The most important occurs at position 158, where a methionine residue is exchanged for valine resulting in a thermolabile, low-activity variant (3-4-fold decrease) [10, 11] . A major part of research on COMT has been devoted to the study of diseases associated with COMT alleles, suggesting some relevance in relation to alcoholism [12] , schizophrenia [13] , bipolar disorder and other cognitive disturbances [14, 15] , as well as to oestrogenrelated cancer types (breast, prostate and ovarian) [16] [17] [18] [19] .
PTMs (post-translational modifications) are important for understanding protein differentiation beyond genetic variation. Various types of PTMs can influence enzyme activity and binding properties as well as protein localization and stability. Phosphorylation is widely distributed among proteins, regulated by protein kinases and phosphatases, and is especially important for activity regulation and cell signalling.
We have previously demonstrated the presence of three COMT variants in soluble and sediment fractions from rat liver autophagosomes by means of two-dimensional gel-electrophoretic protein separation and mass-spectrometric protein identification [20] . In the present study we have used two-dimensional Abbreviations used: ACN, acetonitrile; CID, collision-induced dissociation; COMT, catechol O-methyltransferase; DTT, dithiothreitol; ESI-IT-MS/MS, electrospray ionization with ion-trap tandem MS; FA, formic acid; HRP, horseradish peroxidase; IEF, isoelectric focusing; IMAC, immobilized metal affinity column; IPG, immobilized pH gradient; LC3, microtubule-associated protein 1, light chain 3; LC3-II, the membrane-bound form of LC3; L-COMT, long variant of COMT; LDH, lactate dehydrogenase; MALDI-TOF, matrix-assisted laser-desorption ionization-time-of-flight; PEMT1, phosphatidylethanolamine Nmethyltransferase 1; PNS, postnuclear supernatant; PTM, post-translational modification; S-COMT, short variant of COMT; SOD1, superoxide dismutase 1; TBS, Tris-buffered saline; TEMED, N,N,N ,N -tetramethylethylenediamine. 1 To whom correspondence should be addressed (email Per.O.Seglen@rr-research.no).
immunoblotting with a polyclonal COMT antibody (antiserum) to further investigate the distribution and phosphorylation of COMT forms in various rat tissues.
MATERIALS AND METHODS

Preparation of cell and tissue extracts
All animal experimentation was carried out according to the ethical guidelines of The Norwegian National Animal Research Authority and FELASA (Federation of European Laboratory Animal Science Association). Hepatocytes were prepared by twostep collagenase perfusion [21] from the livers of male Wistar rats (average weight 250 g) starved for 18 h. The cells were incubated for 2 h at 37
• C in suspension buffer [21] containing 20 mM pyruvate and 2 mM Mg 2+ . Post-incubated cells were washed with 10 % (w/v) sucrose, electrodisrupted and homogenized with a tight-fitting Dounce homogenizer as described in [22] to produce an approx. 10 % homogenate (cellular wet mass/volume) containing 7.5 % (w/v) sucrose, 10 mM Hepes and 1 mM EDTA (pH 7.3). Part of the homogenate was used to prepare a cytosolic fraction as previously described [22] ; the rest was used to prepare, by centrifugal removal of the nuclei (2 min at 2000 g), a PNS (postnuclear supernatant) [22] that was frozen with liquid air (− 90
• C) and later thawed for further analysis. Whole tissues from brain, submandibular salivary glands, thymus, thyroid gland, kidney, spleen, heart, lung, testis and liver (for comparison with the purified hepatocytes) were removed from rats post mortem and immediately frozen with liquid air. The tissues were subsequentally thawed on ice (0 • C), homogenized in 7.5 % sucrose, and PNS was prepared in the same manner as for hepatocytes. To separate the tissue extracts into a sedimentable (membrane) fraction and a soluble fraction, the PNS preparations were centrifuged for 2 h at 20 000 rev./min in a Sorvall RC6 highspeed centrifuge (Kendro) with an SS34 rotor.
IEF (isoelectric focusing) and SDS/PAGE
For two-dimensional protein separation, PNS preparations were solubilized with 4 vol. of sample buffer [7 M urea, 2 M thiourea, 2 % CHAPS, 65 mM DTT (dithiothreitol) and 5 % Pharmalyte] and 350 μl samples containing 200 μg of protein were loaded on to 18 cm IPG (immobilized pH gradient) strips, pH 4-7 or pH 3-10 (Immobiline Drystrips). Isoelectric focusing was performed overnight (for a total of 27 500 Vh) in an Ettan IPGphor IEF apparatus (GE Health Biosciences).
After the IEF, the IPG strips were equilibrated in a buffer containing 1 % SDS, 6 M urea, 65 mM Tris/HCl and 65 mM DTT (pH 8.8) for 15 min, then for another 15 min in a similar buffer where DTT was replaced by 240 mM iodoacetamide. Each strip was finally cut to an 8.6 cm length (covering the pI region 4.7-6.0), placed on top of a vertical 12 % polyacrylamide gel cast with 0.1 % SDS, 0.1 % ammonium persulfate, 0.4 M Tris and 0.04 % TEMED (N,N,N ,N -tetramethylethylenediamine), and electrophoresed in a Bio-Rad Mini-Protean 3 apparatus at 200 V for 45 min.
For one-dimensional protein separation (SDS/PAGE), the PNS was solubilized by adding a small volume (1/5) of concentrated Laemmli buffer [23] to final concentrations of 2 % (w/v) SDS, 50 mM Tris/HCl, 100 mM DTT, 0.002 % Bromophenol Blue and 5 % glycerol (pH 6.8). After heating at 95
• C for 5 min, samples containing 20 μg of protein were electrophoresed on 12 % polyacrylamide gels as described above.
Immunoblotting
For immunoblotting, the proteins were transferred to a 0.45 μm PVDF membrane (Millipore) using a Bio-Rad Protean 3 TransBlot Cell apparatus at 100 V for 60 min. The gel and membrane were surrounded by Towbin's transfer buffer containing 20 % methanol and 25 mM Tris/glycine (pH 8.3). After completed transfer, the membranes were washed with methanol followed by incubation for 2 h in TBS (Tris-buffered saline; 20 mM Trizma base and 136.9 mM NaCl, pH 7.6) containing 0.1 % Tween 20 and 5 % (w/v) non-fat dried skimmed milk powder. Primary antibody was added and the membranes were incubated overnight at 4
• C; a secondary antibody conjugated with HRP (horseradish peroxidase) was then added, followed by 30 min incubation at room temperature (22 • C) with mild agitation. After each incubation the membranes were washed three times with TBS for 15 min. The Immobilon chemiluminescence kit (Millipore) was used with a peroxidase substrate to illuminate immunostained proteins. Detection was performed with a Syngene ChemiGenius camera and the GeneSnap software tool (Syngen).
Tryptic digestion and phosphopeptide enrichment
Coomassie-Blue-stained (0.08 % Coomassie Blue G-250 in buffered 20 % methanol) protein bands on one-dimensional gels were excised with a sterile scalpel, whereas a stainless-steel tube (with an inner diameter of 0.7 mm) was used for excision of protein spots from silver-stained two-dimensional gels [20] . The excised gel pieces were subjected to reduction, alkylation and finally tryptic digestion as previously described [20] .
For phosphopeptide enrichment, 10 μl of a tryptic proteolysate was applied on top of an adsorption column prepared by adding 5 μl of titanium oxide slurry to a GEloader tip (Eppendorf). After washing with 70% (v/v) ACN (acetonitrile), the remaining adsorbed peptides were eluted with 25 mM ammonium bicarbonate (pH 8.0), desalted by ZipTipping (μC 18 ; Millipore) and mixed with an equal volume of 2,5-dihydrobenzoic acid matrix solution in 1 % (v/v) phosphoric acid and 50 % (v/v) ACN.
MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS
For MALDI-TOF MS of the phosphopeptide-enriched preparations described above, 2 μl of the peptide-matrix mixture was spotted directly on to a MALDI plate and analysed in a MALDI-TOF instrument (Voyager DePro) from Applied Biosystems. Ordinary tryptic peptides were treated and analysed as reported previously [20] .
ESI-IT-MS/MS (electrospray ionization-based ion-trap tandem MS)
For analysis of tryptic proteolysates by ESI-IT-MS/MS, freezedried peptides were dissolved in 10 μl of 5 % ACN and 0.1 % FA (formic acid) in water; this solution was also used as the liquid chromatographic mobile phase. A sample volume of 2.0 μl was injected per run, a minimum of two parallel runs being used for each identification. The initial gradient was set at 5 % ACN (with 0.1 % FA) increasing to 80% ACN (with 0.1 % FA) in 15 min.
The instrument set-up included an Agilent MSD XCT ion-trap mass spectrometer with an HPLC Chip electrospray interface and an 1100-series nano-LC (Agilent Technologies). The separation column was a 40 nL C 18 Sorbax ZX Agilent Chip with dimensions 75 μm × 43 mm. The ion-trap configuration was standard enhanced (8100 m/z/s) positive mode, scanning range 300-1800 m/z for MS1 and 100-2200 m/z for MS2, with five precursor scans and active exclusion after two spectra for 1 min. Optional neutral loss MS3 was enabled for phosphate groups (m/z: 32.3, 40.0, 49.0, 80.0 and 98.0). The counter-electrode voltage was set to reach a current of 70 nA and the ion current count smart target at 400 000 with no rolling average.
Data analysis
Completed data sets were analysed with Spectrum Mill (Agilent Technologies), using 13.0 as the summed spectrum peptide score threshold for proteins and 10.0 for individual peptides with a spectral peak intensity percentage above 70. Swiss-Prot's annoted database (build 70.2) was used for database searches (http://expasy.org). The mass tolerance was set to 0.7 Da for fragment ions and 2.5 Da for precursor ions. MASCOT (http://www. matrixscience.com) was used for peptide mass fingerprinting, with a mass tolerance of 100 p.p.m. for ion-trap data and 50 p.p.m. for MALDI-TOF data.
Protein measurement
Kits from Pierce were used for determination of protein concentrations in PNS, either based on the method of Bradford [24] or on the BCA (bicinchoninic acid) method [25] . Absorbance was measured on an iEMS Reader MF spectrophotometer (Labsystems) at a wavelength of 540 nm.
Chemicals
Our anti-COMT antiserum was made to order by Sigma-Genosys, using immunization of rabbits with the peptide AKPGDPQS-VLEAIDTYC [amino acids 17-33 in rat S-COMT (small variant of COMT), numbered according to Swiss-Prot accession number P22734-2]. The polyclonal antibody against LC3 (microtubuleassociated protein 1, light chain 3) was made to order by BioGenes GmbH through immunization of rabbits with the cysteinylated N-terminal 14-amino acid peptide PSEKTFKQR-RSFEQ. A rabbit antiserum against PEMT1 (phosphatidylethanolamine N-methyltransferase 1) was kindly donated by Dr D. E. Vance (Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada), whereas the rabbit antiserum against SOD1 (superoxide dismutase 1; CuZn-SOD) was a gift from Dr J. D. Crapo (Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO, U.S.A.). A goat antibody (ab2101) against LDH (lactate dehydrogenase) was from Abcam. HRP-conjugated anti-rabbit IgG was purchased from Cell Signaling Technologies, and HRP-conjugated anti-goat IgG was from Santa Cruz Biotechnology. Modifed sequence-grade trypsin was obtained from Promega. Sodium carbonate, silver nitrate, sodium thiosulfate, methanol, trifluoroacetic acid, urea, thiourea and acetonitrile were from Merck.
α-Cyano-4-hydroxycinnamic acid, ammonium bicarbonate, ammonium persulfate, Tween 20, Trizma base, EDTA, Bromophenol Blue, glycine, TEMED and glycerol were bought from Sigma-Aldrich. SDS and acrylamide were obtained from Bio-Rad Laboratories. FA and dimethylfluoride were purchased from Fluka. Water was purified with the Milli-Q Ultrapure system from Millipore with a minimum resistance of 18.2 M /cm. Titanium oxide slurry was kindly donated by Dr Olav Mjaavatten (PROBE, University of Bergen, Bergen, Norway).
RESULTS
Tissue distribution of COMT
We have recently identified three rat hepatocellular S-COMT variants in silver-stained two-dimensional gels, two of which bound selectively to autophagosomal membranes [20] . One of the latter was, furthermore, found to be phosphorylated, a modification not previously reported for COMT. To allow a more detailed study of COMT forms and their possible PTMs in rat tissues, we have developed a polyclonal rabbit antibody (antiserum) against the N-terminal region of rat S-COMT. This antibody was used for immunoblotting of tissue lysates fractionated by one-dimensional or two-dimensional SDS/PAGE.
Pronounced differences were found in the tissue expression patterns of the two major COMT forms, the small form (S-COMT, banding at ∼ 24 kDa) and the large form [L-COMT (large variant of COMT), banding at ∼ 28 kDa] being well resolved on onedimensional gels ( Figure 1 ). As shown in Figure 1(A) , liver tissue displayed a very strong expression of S-COMT and a very weak expression of L-COMT. The latter was sometimes seen to be split into two bands at high protein loading ( Figure 1B) , indicating the presence of two L-COMT variants. Kidney also showed a preferential expression of S-COMT, whereas in other tissues studied (brain, spleen, lung, submandibular salivary gland, testis, thymus and heart), L-COMT was the predominant form. Most tissues contained detectable amounts of both S-COMT and L-COMT, but in the thyroid gland COMT seemed to be absent altogether, or expressed at a very low level ( Figure 1A ). As in the liver, two L-COMT species could be discerned in the brain and in the salivary gland, but not in the kidney ( Figure 1B) .
To check to what extent S-COMT and L-COMT were membrane-bound, PNS preparations were centrifuged at high speed to sediment all cellular membranes. As shown in Figure 1(B) , the sedimentable fraction of S-COMT was relatively minor both in the liver and kidney, whereas the amounts of L-COMT in the two fractions were relatively similar in liver, kidney or brain preparations. Only in the salivary gland was L-COMT clearly more abundant in the sediment than in the supernatant (S-COMT levels were too low in brain and salivary glands to allow a meaningful interpretation). Designation of the two major COMT forms as soluble and membrane-bound [6, 7] thus does not seem to be very meaningful; it would seem better to distinguish between small (S-COMT) and large (L-COMT) forms. This conclusion is supported by our previous study, where we found two S-COMT forms associated with autophagosomal membranes [20] .
To verify the relative purity of the sedimentable (membrane) and non-sedimentable fractions, two known cytosolic and two known membrane-bound proteins were immunoblotted as controls. As shown in Figure 1(C) , the cytosolic enzymes, SOD1 [26] and LDH [27] , were both predominantly non-sedimentable, whereas the membrane-associated proteins, PEMT1 [28] and LC3-II (the membrane-bound form of LC3) [29] were both predominantly sedimentable. These subcellular markers thus support our conclusions regarding the distribution of the COMT forms.
Two-dimensional immunoblotting reveals the presence of many COMT forms
To further investigate the multiplicity of COMT forms, we performed a two-dimensional gel fractionation and immunoblotting of homogenates from whole rat liver (Figure 2A Figure 2A ) could be detected in the immunoblot of the tissue with the highest COMT abundance, i.e. liver. Two of these were the L-COMT variants mentioned above; the other five were S-COMT variants. No additional variants were seen in any of the other tissues, but all of the tissues displayed several COMT forms (summarized in Table 1 ). Form 1, a phosphorylated species (see below) was apparently confined to the liver, whereas the other phosphorylated species, form 2, was also found in thymus ( Figure 2B ), brain ( Figure 2C ) and kidney ( Figure 2D ). Form 3, highly expressed in the liver, was present in all tissues examined, whereas form 4 was only seen in liver and testis ( Figure 2E ). Form 6 was found in liver, kidney and thymus. The two large (L-COMT) forms 5 and 7 were both expressed in four of the tissues, but kidney had only form 7, and heart only form 5. The fact that heart tissue produced only two COMT spots on twodimensional gels, 5 and (very little) 3, was surprising in view of the band multiplicity indicated on one-dimensional gels ( Figure 1A , last lane), perhaps reflecting some secondary fragmentation in this tissue (compare the diffuse staining in Figure 1A ).
Verification of COMT spot identities by MS
To verify the identities of the many immunostained putative COMT forms, we performed a mass spectrometric analysis of those silver-stained spots in high-resolution two-dimensional gels that coincided with immunostained spots from liver cells ( Figure 3A ) or brain ( Figure 3B) . Six of the seven hepatocellular COMT forms could be recognized by silver staining and identified by MALDI-TOF tryptic fingerprinting; only spot 4 overlapped too much with its neighbouring spots 3 and 6 to be resolved and verified. Among brain proteins fractionated on two-dimensional gels, COMT forms 2 and 7 could be recognized and identified.
For independent identity verification, the two-dimensionalresolved COMT spots from liver and brain were also analysed by MS/MS in an ion-trap instrument where the tryptic peptides, ionized by the nano-electrospray method (ESI-IT-MS/MS), could be further fragmented by CID (collision-induced dissociation) to obtain the full amino acid sequence of the peptide. Interestingly, the two mass-spectrometric methods yielded relatively complementary (non-overlapping) peptide identifications, resulting in high sequence coverage (Figure 4) . This is probably due to the preference of MALDI-TOF MS for shorter peptides and of ESI-IT-MS/MS for longer peptides, reflecting their different analyte ionization mechanisms.
The sequence coverage was above 50 % for all of the MALDIanalysed hepatocellular COMT forms except form 5, yielding highly significant identifications (P values ranging from 4 × 10 −3 to 5 × 10 −8 ), and even the identification of form 5 was significant, with a sequence coverage of 22 % ( Table 2 ). The identifications of the two brain forms were also highly significant, with P values of 2 × 10 −3 and 7 × 10 −4 . N-terminal, as well as C-terminal, tryptic peptides were obtained from spots 2, 3 and 6, ascertaining that all three represented full-length S-COMT species, and that no proteolytic processing or secondary proteolytic degradation had taken place. The moderate differences in electrophoretic mobility, e.g. between spots 2 and 6, would, therefore, have to be due to non-proteolytic modifications.
Tryptic fingerprinting of the two L-COMT forms (spots 5 and 7) yielded a non-phosphorylated C-terminal peptide from spot 7, but no N-terminal peptides were recovered, despite the presence of potential cleavage sites for trypsin after Arg 19 , Lys 47 and Arg 50 . Their classification as full-length L-COMT is, therefore, reliant on their high molecular mass, as indicated by their electrophoretic mobility on one-dimensional and two-dimensional gels.
Mass-spectrometric identification and localization of S-COMT phosphorylation
The presence of several pI variants of both S-COMT and L-COMT must be due to some form of post-translational modification. In an attempt to identify such modifications, the mass spectra were Liver X X X X X X X Thymus X X X X X B r a i n X X X X Kidney X X X X Testis X X X Heart X X studied in detail. Since we previously discovered an N-acetylated and phosphorylated COMT form associated with autophagic membranes [20] , particular emphasis was placed on these two types of modification. To enrich our rat hepatocytic preparations for phosphopeptides, the tryptic proteolysates from the abundant S-COMT forms 2 and 3 were adsorbed on to IMACs (immobilized metal affinity columns) and eluted before analysis by MALDI-TOF MS. Figure 5 compares a MALDI mass spectrum of a non-enriched proteolysate from two-dimensional spot 3 with a phosphopeptideenriched proteolysate from spot 2. A large number of peptides were found to match unmodified COMT sequences in the spectrum from spot 3 ( Figure 5A ), including the C-terminal peptide AIYQGPSSPDKS at m/z 1249.54 ( Figure 4A ). Only four out of the five prominent peptide peaks from spot 2 could be identified as unmodified COMT peptides ( Figure 5B ), also found in spot 3. The fifth peak (m/z 1329.53) corresponded to the C-terminal AIYQGPSSPDKS peptide modified by the addition of 80 Da extra mass, indicating a phosphorylation not found in spot 3. No other phosphorylations were found in either phosphopeptide-enriched or non-enriched proteolysates from spots 2 or 3.
Phosphorylation of the C-terminal tryptic peptide was also detected in the liver-specific spot 1, but no other phosphorylated peptides could be detected in any of the other S-COMT or L-COMT forms.
The phosphorylated C-terminal peptide from S-COMT form 2 had four possible sites for phosphorylation since it contained three serine residues and one tyrosine residue. An increase of 80 Da could also be an indication of other modifications, e.g. sulfation of a tyrosine residue. To verify the phosphorylation and to establish the exact phosphorylation site, the C-terminal peptides from spots 2 and 3 were subjected to ESI-IT-MS/MS. The sequences obtained by CID (Figure 6 ) strongly suggested the phosphorylation site to be at Ser 217 in S-COMT, corresponding to Ser 260 in L-COMT (in the present study, we follow the latter denotation).
To distinguish between phosphorylation at Ser 259 and Ser 260 , a close examination of the fragmentation pattern was needed. If Ser 259 were to have a phosphorylation, neither a peak at 717 m/z corresponding to the b 7 -ion (AIYQGPS), nor a peak Cytoplasmic extracts (PNS) from purified rat hepatocytes (A) or whole rat brain (B) were solubilized in urea/thiourea/CHAPS and subjected to two-dimensional gel electrophoresis on large (18-cm-width) 12 % gels, pH range 4-7, followed by MS-compatible silver staining. The encircled spots were excised and identified as COMT forms by MALDI-TOF MS. For liver spots 5 and 7, samples from several gels were pooled prior to analysis.
Figure 4 Mapping of the amino acid sequences of S-COMT and L-COMT forms
The sequence coverage for L-COMT (A; spot 7; 62.1 % coverage) and S-COMT (B; spot 3; 94.5 % coverage) is the result of the combined peptide analysis data obtained from MALDI-TOF MS (shown in italics), ESI-IT-MS/MS (shown in bold) or both (shown in bold italics). S * , phosphoserine.
at 613 m/z assigned to the y 5 -ion (SKDSPpS) should have appeared. Furthermore, since the y 5 ion (m/z 533) in the nonphosphorylated peptide ( Figure 6A ) is prominent, a similar peak would be expected for fragmentation of a peptide with phosphoSer 259 . The phosphorylated serine residue would thus seem to be Ser 260 .
The likelihood of a phosphate group at Ser 260 was confirmed by prediction analysis according to NetPhos 2.0 [30] from the Center for Biological Sequence Analysis at the Technical University of Denmark (http://www.cbs.dtu.dk), which suggested Ser 260 as the most likely phosphorylation site in the full-length COMTsequence (Figure 7 ). Ser 259 also had a high probability for the same Table 2 Properties of COMT forms Analytical parameters of COMT forms from liver (isolated hepatocytes) and brain (whole tissue). Spots excised from silver-stained two-dimensional gels ( Figure 3) were trypsinized, analysed by MALDI-TOF MS and identified on the basis of the tryptic fingerprint. Sequence coverage refers to the relative length of the full protein sequence covered by the identified peptides from S-COMT (spots 1, 2, 3 and 6) or L-COMT (spots 5 and 7). The reliability of identification (probability of a positive identification being false) was calculated by the MASCOT program; P values < 0.05 were considered significant. The full-length form (L-COMT) was identified by its molecular mass (nominal value 29.6 kDa, detected at 28 kDa). Phosphorylation at Ser 260 (full-length numbering, S-COMT starting at Gly 51 ) was detected by an extra 80 Da mass addition to the C-terminal peptide, verified by ESI-IT-MS/MS. N-terminal acetylation indicates an acetylated N-terminal glycine residue in the N-terminal peptide from the S-COMT forms. Other modifications are implicated on the basis of the acid pI shifts relative to the most basic forms of S-COMT (spot 6) and L-COMT (spot 7). X and − indicate the presence or absence of a given examined property; blanks indicate that no determination was made. This is mostly the case for spot 4, which overlaps too much with the adjacent spots (3 and 6) to be excisable from silver-stained gels.
Properties
Spot number . . . modification, but we were not able to find any phosphoserine at that site or at other predicted sites such as the triple serine motif at 229-231. We furthermore used this search engine to evaluate a possible kinase with affinity for the Ser 260 site, but the most likely predicted kinase, Cdk5 (cyclin-dependent kinase 5), displayed only a probability score of 0.55.
Other COMT modifications
Apart from the phosphorylation at Ser 260 and the occasional methionine oxidation (mostly a secondary in vitro phenomenon), no modifications were detected in any of the COMT-derived peptides by MS/MS. MALDI-TOF, on the other hand, identified N-acetylation in three of the S-COMT forms, including the phosphorylated form 2 ( Table 2 ). Since no tryptic peptides were obtained from the N-terminal region of the L-COMT forms, we do not know if these forms (5 and 7) may carry modifications in this region. Certainly the pI difference between forms 5 and 7 shows the presence of as yet unidentified L-COMT modifications. By the same argument, it is clear that the S-COMT forms must carry posttranslational modifications other than N-acetylation and Ser 260 phosphorylation. Additional serine/threonine phosphorylations in S-COMT forms 2 and 3 can be ruled out, because of the extensive sequence coverage of these forms (which includes all serine and threonine sites). Tyrosine phosphorylation(s), however, cannot be excluded, because phosphotyrosine groups are labile and difficult to detect due to the lack of neutral loss in ESI-IT-MS/MS [31, 32] . The NetPhos 2.0 search engine referred to above ( Figure 7 ) suggested a fairly high prediction score (0.969) for phosphorylation of COMT at Tyr 138 , but without experimental support this phosphorylation site remains conjectural.
DISCUSSION
COMT is a vital enzyme in drug metabolism and neural functions; its regulation by post-translational modifications could, therefore, have a major impact on cell function in brain and liver as well as in other tissues. The fact that a common phosphorylated S-COMT form was present both in liver, kidney, brain and thymus could indicate that some as yet unknown form of COMT regulation takes place in these tissues.
Although the phosphorylation at Ser 260 can account for the more acidic pI values of S-COMT forms 1 and 2 relative to forms 3, 4 and 6, we have not found any structural differences that can distinguish between forms 1 and 2, or between forms 3, 4 and 6, despite extensive sequence coverage. Therefore the possibility has to be considered that some of the unknown COMT modifications may represent secondary in vitro artefacts. Although proteolysis did not seem to play any role, the proteins could have become modified in other ways somewhere along the preparation of tissue extracts, or during the lengthy IEF (compare the difference between the one-dimensional and two-dimensional immunoblotting of heart COMT). Both the addition and loss of (labile) protein modifications could occur; in particular, IPGs have inherent problems, e.g. with water binding to proteins, resulting in altered isoelectric points. Oxidation of cysteine residues and methionine residues can also change the migration of spots in the first dimension [33] , despite performing the separation under reducing conditions. Another potential problem is the carbamylation of lysine residues, which may occur with the use of deteriorated urea. However, both carbamylation and oxidation are modifications that can be detected in the mass spectrum.
Another origin of protein variants may be in small and subtle changes in primary structure such as have been reported for
Figure 7 Predicted protein phosphorylation sites in rat COMT
A search for potential protein phosphorylation sites and their putative phosphorylating protein kinases in full-length rat COMT was performed with the search tools NetPhos 2.0 and NetPhosK 1.0 (http://www.cbs.dtu.dk). The probability score range is 0-1; the threshold was set to 0.50. The C-terminal sequence containing the phosphorylation site phospho-Ser 260 is shown in bold.
polymorphisms in human COMT [10, 11] . Although no polymorphisms have been reported for rat COMT, the frequently mutated human Val 158 is preserved as a leucine residue in nonhuman mammals (Leu 151 in the rat; compare with Figure 8 ), and could, by analogy, have a low-activity variant with methionine in position 151. However, since leucine and methionine have a very similar pI, one would not expect a chimaerical mutation to cause a shift in the pI of the protein.
The N-terminal modification that we have identified, which involves removal of the original N-terminal methionine residue and subsequent acetylation of the second residue (glycine in the case of S-COMT) has been suggested previously [34] , and was also detected in one of our autophagosomal COMT variants [20] . In the present study we demonstrate the presence of N-acetylation in three S-COMT forms (2, 3 and 6) . N-acetylation thus does not account for the pI difference between forms 3 and 6, although it cannot be ruled out as a possible distinction between forms 1 and 2. N-acetylation would not be expected in the full-length L-COMT, where proline, the second amino acid, is rarely known to be acetylated.
A putative high-molecular-mass COMT form has been described from brain [14] , but we have failed to detect this form or any other COMT-positive protein above 30 kDa. There has also been a report on several mRNA transcripts present in brain [35] , but it is unclear whether any of these could account for the multiplicity of COMT forms observed in the present study.
Recent comprehensive proteomic mappings of phosphorylation sites have confirmed the phosphorylation at Ser 260 in rat liver COMT [36] and at the corresponding Ser 261 (compare Figure 8 ) in mouse liver COMT [37] . However, these large-scale studies of pooled phosphopeptides could not differentiate between S-COMT and L-COMT, because the two are identical in most of their sequence. In the present study, we have unambiguously detected phospho-Ser 260 in two hepatocellular S-COMT variants, and in one variant in brain, kidney and thymus. Furthermore, it seems clear that this modification is absent from two S-COMT forms and one L-COMT form in the liver, and from one L-COMT form in the brain. Unfortunately, the acidic L-COMT spot 5 was too weak to have its phosphorylation state examined; we cannot, therefore, conclude that only S-COMT is regulated by phosphorylation, although this remains a distinct possibility.
The Ser 260 phosphorylation site is well preserved among mammals (Figure 8 ), suggesting that it may be phosphorylated in other mammals besides rodents. However, although COMT is highly conserved throughout its sequence, the homology is actually lowest in the C-terminal region. Therefore, it remains to be proven that this modification also occurs in humans. It is not known whether a phosphorylation in the tail region of COMT would have an impact on the activity of the enzyme. X-ray crystallography has revealed substrate binding in the vicinity of the tail region (near Glu 242 ), and a modification close to this site could have implications for the substrate binding strength [38, 39] .
COMT proteins have been studied in several tissues besides liver and brain, for example hypothalamus [40] , kidney [41] and duodenum [42] , but the expression levels in liver remain the highest [7] . To our knowledge, no COMT phosphorylation has previously been indicated in any tissue other than the liver.
